Silexan in anxiety disorders: Clinical data and pharmacological background
Open Access
- 19 June 2017
- journal article
- review article
- Published by Taylor & Francis in The World Journal of Biological Psychiatry
- Vol. 19 (6) , 412-420
Abstract
Objectives: Silexan is a lavender oil preparation available in 80-mg capsules. Here we review clinical trials investigating its anxiolytic efficacy, safety and tolerability in humans, as well as preclinical investigations supporting this therapeutic use. Methods: Besides three selected publications reporting preclinical investigations, seven clinical trials are included, of which five had a treatment duration of 6 or 10 weeks. Primary outcome measure was the HAM-A total score reduction, while single items were assessed with regard to effects on concomitant depressive symptoms and on quality of sleep. Results: In patients with subthreshold (subsyndromal) anxiety or generalised anxiety disorder (GAD), an anxiolytic effect of Silexan was evident after 2 weeks. HAM-A total score reductions between baseline and end of treatment were significantly superior to placebo in patients with subthreshold anxiety and comparable with those achieved under lorazepam or paroxetine in patients with GAD. In addition, Silexan had beneficial effects on typical concomitant symptoms of anxiety disorders, such as impaired sleep, somatic complaints, co-morbid depression or decreased quality of life. Except for mild gastrointestinal symptoms, Silexan did not induce any adverse effects and did not cause drug interactions, sedation or withdrawal symptoms at daily doses of 80 or 160 mg. Conclusions: Silexan is a safe and effective treatment in anxiety disorders.Keywords
This publication has 32 references indexed in Scilit:
- Effects of Silexan on the Serotonin-1A Receptor and Microstructure of the Human Brain: A Randomized, Placebo-Controlled, Double-Blind, Cross-Over Study with Molecular and Structural NeuroimagingInternational Journal of Neuropsychopharmacology, 2014
- No Interacting Influence of Lavender Oil Preparation Silexan on Oral Contraception Using an Ethinyl Estradiol/Levonorgestrel CombinationDrugs in R&D, 2014
- The prevalence and burden of subthreshold generalized anxiety disorder: a systematic reviewBMC Psychiatry, 2014
- Drug Cocktail Interaction Study on the Effect of the Orally Administered Lavender Oil Preparation Silexan on Cytochrome P450 Enzymes in Healthy VolunteersDrug Metabolism and Disposition, 2013
- Anxiolytic-like effect of lavender essential oil inhalation in mice: Participation of serotonergic but not GABAA/benzodiazepine neurotransmissionJournal of Ethnopharmacology, 2013
- Anxiety Disorders: Sex Differences in Prevalence, Degree, and Background, But Gender-Neutral TreatmentGender Medicine, 2007
- Discontinuation symptoms in depression and anxiety disordersInternational Journal of Neuropsychopharmacology, 2005
- Anxiety and depression are associated with unhealthy lifestyle in patients at risk of cardiovascular diseaseAtherosclerosis, 2005
- What people say about their general practitioners' treatment of anxiety and depressionMedical Journal of Australia, 2001
- One-year prevalence of subthreshold and threshold DSM-IV generalized anxiety disorder in a nationally representative sampleDepression and Anxiety, 2001